1. Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors
2. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
3. Study to Evaluate the Safety, Pharmacokinetics,
and Activity of GDC-1971
in Combination With Either Osimertinib in Participants With Unresectable,
Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With
Cetuximab in Participants With Metastatic Colorectal Cancer, NCT05954871, https://classic.clinicaltrials.gov/ct2/show/NCT05954871?term=GDC-1971&draw=2&rank=2.
4. A Study to Evaluate the Safety, Pharmacokinetics,
and Activity of
GDC-1971 in Combination With Atezolizumab in Participants With Locally
Advanced or Metastatic Solid Tumors, NCT05487235, https://classic.clinicaltrials.gov/ct2/show/NCT05487235?term=GDC-1971&draw=2&rank=1.
5. A Phase Ia/Ib Dose-Escalation and Dose-Expansion
Study Evaluating
the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single
Agent and in Combination With Other Anti-cancer Therapies in Patients
With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation, NCT04449874, https://classic.clinicaltrials.gov/ct2/show/NCT04449874.